The effect of topical sodium cromoglycate on intranasal histamine challenge in allergic rhinitis

M. A. Birchall, J. C. Henderson, J. M. Studham, N. B. Pride, R. W. Fuller

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Topical sodium cromoglycate is used to treat allergic diseases of the upper and lower airways. To investigate its mechanisms of action, intranasal histamine challenge was used in nine subjects with perennial allergic rhinitis. After a preliminary day where subjects' reactivity thresholds (D100) for histamine were determined, intranasal sodium cromoglycate was administered in a double-blind, placebo-controlled fashion. Graded (D100/3, D100, D100X3), sequential challenges were performed on days 1 and 21 of each course, and responses measured by changes in nasal airway resistance, sneezes, secretion volume and secretion content: total protein, lysozyme and mucin. After a single dose of sodium cromoglycate, there was no change in resistance, but secretion volumes fell significantly (3.12 ml/5 min c.i.2.83-3.4; placebo 3.61,c.i.3.32-3.90: P = 0.026). After a 3-week-course, there was a significant fall in resistance (4.29 cm H2O/l/s, c.i.3.85-4.72; placebo 5.45,c.i.5.01-5.88: P < 0.0001). No change in other parameters was observed. Thus, in perennial allergic rhinitis, intranasal sodium cromoglycate has both short- and long-term effects on nasal reactivity to histamine challenge. Acutely, there is a reduction in nasal lavage fluid volume which may be the result of reduced irritant receptor activity. After a 3-week course, there is a reduction in nasal resistance responses, a possible anti-inflammatory effect.

Original languageEnglish (US)
Pages (from-to)521-525
Number of pages5
JournalClinical Otolaryngology and Allied Sciences
Volume19
Issue number6
StatePublished - 1994
Externally publishedYes

Fingerprint

Cromolyn Sodium
Histamine
Rhinitis, Allergic, Perennial
Nose
Placebos
Nasal Lavage Fluid
Airway Resistance
Irritants
Mucins
Muramidase
Anti-Inflammatory Agents
Allergic Rhinitis
Proteins

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Birchall, M. A., Henderson, J. C., Studham, J. M., Pride, N. B., & Fuller, R. W. (1994). The effect of topical sodium cromoglycate on intranasal histamine challenge in allergic rhinitis. Clinical Otolaryngology and Allied Sciences, 19(6), 521-525.

The effect of topical sodium cromoglycate on intranasal histamine challenge in allergic rhinitis. / Birchall, M. A.; Henderson, J. C.; Studham, J. M.; Pride, N. B.; Fuller, R. W.

In: Clinical Otolaryngology and Allied Sciences, Vol. 19, No. 6, 1994, p. 521-525.

Research output: Contribution to journalArticle

Birchall, MA, Henderson, JC, Studham, JM, Pride, NB & Fuller, RW 1994, 'The effect of topical sodium cromoglycate on intranasal histamine challenge in allergic rhinitis', Clinical Otolaryngology and Allied Sciences, vol. 19, no. 6, pp. 521-525.
Birchall, M. A. ; Henderson, J. C. ; Studham, J. M. ; Pride, N. B. ; Fuller, R. W. / The effect of topical sodium cromoglycate on intranasal histamine challenge in allergic rhinitis. In: Clinical Otolaryngology and Allied Sciences. 1994 ; Vol. 19, No. 6. pp. 521-525.
@article{123c2ebad3dd4271870e60c164fbbea2,
title = "The effect of topical sodium cromoglycate on intranasal histamine challenge in allergic rhinitis",
abstract = "Topical sodium cromoglycate is used to treat allergic diseases of the upper and lower airways. To investigate its mechanisms of action, intranasal histamine challenge was used in nine subjects with perennial allergic rhinitis. After a preliminary day where subjects' reactivity thresholds (D100) for histamine were determined, intranasal sodium cromoglycate was administered in a double-blind, placebo-controlled fashion. Graded (D100/3, D100, D100X3), sequential challenges were performed on days 1 and 21 of each course, and responses measured by changes in nasal airway resistance, sneezes, secretion volume and secretion content: total protein, lysozyme and mucin. After a single dose of sodium cromoglycate, there was no change in resistance, but secretion volumes fell significantly (3.12 ml/5 min c.i.2.83-3.4; placebo 3.61,c.i.3.32-3.90: P = 0.026). After a 3-week-course, there was a significant fall in resistance (4.29 cm H2O/l/s, c.i.3.85-4.72; placebo 5.45,c.i.5.01-5.88: P < 0.0001). No change in other parameters was observed. Thus, in perennial allergic rhinitis, intranasal sodium cromoglycate has both short- and long-term effects on nasal reactivity to histamine challenge. Acutely, there is a reduction in nasal lavage fluid volume which may be the result of reduced irritant receptor activity. After a 3-week course, there is a reduction in nasal resistance responses, a possible anti-inflammatory effect.",
author = "Birchall, {M. A.} and Henderson, {J. C.} and Studham, {J. M.} and Pride, {N. B.} and Fuller, {R. W.}",
year = "1994",
language = "English (US)",
volume = "19",
pages = "521--525",
journal = "Clinical Otolaryngology",
issn = "1749-4478",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The effect of topical sodium cromoglycate on intranasal histamine challenge in allergic rhinitis

AU - Birchall, M. A.

AU - Henderson, J. C.

AU - Studham, J. M.

AU - Pride, N. B.

AU - Fuller, R. W.

PY - 1994

Y1 - 1994

N2 - Topical sodium cromoglycate is used to treat allergic diseases of the upper and lower airways. To investigate its mechanisms of action, intranasal histamine challenge was used in nine subjects with perennial allergic rhinitis. After a preliminary day where subjects' reactivity thresholds (D100) for histamine were determined, intranasal sodium cromoglycate was administered in a double-blind, placebo-controlled fashion. Graded (D100/3, D100, D100X3), sequential challenges were performed on days 1 and 21 of each course, and responses measured by changes in nasal airway resistance, sneezes, secretion volume and secretion content: total protein, lysozyme and mucin. After a single dose of sodium cromoglycate, there was no change in resistance, but secretion volumes fell significantly (3.12 ml/5 min c.i.2.83-3.4; placebo 3.61,c.i.3.32-3.90: P = 0.026). After a 3-week-course, there was a significant fall in resistance (4.29 cm H2O/l/s, c.i.3.85-4.72; placebo 5.45,c.i.5.01-5.88: P < 0.0001). No change in other parameters was observed. Thus, in perennial allergic rhinitis, intranasal sodium cromoglycate has both short- and long-term effects on nasal reactivity to histamine challenge. Acutely, there is a reduction in nasal lavage fluid volume which may be the result of reduced irritant receptor activity. After a 3-week course, there is a reduction in nasal resistance responses, a possible anti-inflammatory effect.

AB - Topical sodium cromoglycate is used to treat allergic diseases of the upper and lower airways. To investigate its mechanisms of action, intranasal histamine challenge was used in nine subjects with perennial allergic rhinitis. After a preliminary day where subjects' reactivity thresholds (D100) for histamine were determined, intranasal sodium cromoglycate was administered in a double-blind, placebo-controlled fashion. Graded (D100/3, D100, D100X3), sequential challenges were performed on days 1 and 21 of each course, and responses measured by changes in nasal airway resistance, sneezes, secretion volume and secretion content: total protein, lysozyme and mucin. After a single dose of sodium cromoglycate, there was no change in resistance, but secretion volumes fell significantly (3.12 ml/5 min c.i.2.83-3.4; placebo 3.61,c.i.3.32-3.90: P = 0.026). After a 3-week-course, there was a significant fall in resistance (4.29 cm H2O/l/s, c.i.3.85-4.72; placebo 5.45,c.i.5.01-5.88: P < 0.0001). No change in other parameters was observed. Thus, in perennial allergic rhinitis, intranasal sodium cromoglycate has both short- and long-term effects on nasal reactivity to histamine challenge. Acutely, there is a reduction in nasal lavage fluid volume which may be the result of reduced irritant receptor activity. After a 3-week course, there is a reduction in nasal resistance responses, a possible anti-inflammatory effect.

UR - http://www.scopus.com/inward/record.url?scp=0028608008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028608008&partnerID=8YFLogxK

M3 - Article

C2 - 7895384

AN - SCOPUS:0028608008

VL - 19

SP - 521

EP - 525

JO - Clinical Otolaryngology

JF - Clinical Otolaryngology

SN - 1749-4478

IS - 6

ER -